November 2023

– Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies bring to patients – ORSERDU data reinforce its key role in the treatment of ER+, HER2- advanced or metastatic breast cancer (mB

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: